AnaptysBio, Inc. (ANAB) vs Novavax, Inc. (NVAX)

AnaptysBio, Inc. and Novavax, Inc. are both Biotechnology companies. AnaptysBio, Inc. and Novavax, Inc. are of similar size ($1.4B and $1.3B). Novavax, Inc. has negative trailing earnings, so its P/E is not meaningful; AnaptysBio, Inc. trades at 73.6×. AnaptysBio, Inc. grew revenue faster over the last twelve months: 95.2% against −61.3%. AnaptysBio, Inc. has the higher net margin (6.54% vs −18.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, AnaptysBio, Inc. leads on 11 and Novavax, Inc. on 5.

Valuation

Metric ANAB NVAX Biotechnology median
P/E 73.58 n/m 10.01
P/S 5.66 3.19 9.02
P/B 65.39 n/m 2.13
Price to free cash flow 308.76 n/m 24.99
EV/EBITDA 13.90 n/m 0.64
EV/Sales 5.04 2.39 9.01
Earnings yield 1.36% (5.79%) (34.01%)
Free cash flow yield 0.32% (18.74%) (24.62%)

Profitability

Metric ANAB NVAX Biotechnology median
Gross margin 100.00% 78.01% 70.18%
Operating margin 36.14% (21.23%) 0.00%
Net margin 6.54% (18.64%) 0.00%
Free cash flow margin 0.00% (59.25%) 0.00%
Return on equity (365.73%) 41.08% (50.72%)
Return on assets 4.76% (7.42%) (45.56%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANAB NVAX Biotechnology median
Revenue growth (TTM) 95.19% (61.33%) 7.42%
EPS growth (last fiscal year) 91.02% 309.76% 29.36%
Revenue growth, 5-year CAGR 25.62% 18.76% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANAB NVAX Biotechnology median
Debt to equity 0.17 (1.35) 0.00
Current ratio 8.40 2.15 4.72
Net debt to EBITDA (6.84) (1.04) 1.01

Dividend

Metric ANAB NVAX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ANAB NVAX Biotechnology median
Market cap 1.36b 1.31b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack